Regeneron

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Trade Regeneron 24 hours a day, five days a week on Robinhood.

Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.

About REGN

Regeneron Pharmaceuticals, Inc. is a biotechnology company, which engages in the discovery, invention, development, manufacture, and commercialization of medicines. Its product portfolio includes the following brands: Dupixent, Evkeeza, Eylea, Inmazeb, and Kevzara. 

CEO
Leonard S. Schleifer
CEOLeonard S. Schleifer
Employees
15,410
Employees15,410
Headquarters
Tarrytown, New York
HeadquartersTarrytown, New York
Founded
1988
Founded1988
Employees
15,410
Employees15,410

REGN Key Statistics

Market cap
87.27B
Market cap87.27B
Price-Earnings ratio
18.85
Price-Earnings ratio18.85
Dividend yield
0.48%
Dividend yield0.48%
Average volume
905.79K
Average volume905.79K
High today
$764.65
High today$764.65
Low today
$723.01
Low today$723.01
Open price
$726.18
Open price$726.18
Volume
1.16M
Volume1.16M
52 Week high
$821.11
52 Week high$821.11
52 Week low
$541.00
52 Week low$541.00

Stock Snapshot

With a market cap of 87.27B, Regeneron(REGN) trades at $767.61. The stock has a price-to-earnings ratio of 18.85 and currently yields dividends of 0.48%.

As of 2026-08-03, Regeneron(REGN) stock has fluctuated between $723.01 and $764.65. The current price stands at $767.61, placing the stock +6.2% above today's low and +0.4% off the high.

Regeneron(REGN) shares are trading with a volume of 1.16M, against a daily average of 905.79K.

During the past year, Regeneron(REGN) stock moved between $541.00 at its lowest and $821.11 at its peak.

During the past year, Regeneron(REGN) stock moved between $541.00 at its lowest and $821.11 at its peak.

REGN News

Simply Wall St 2d
Regeneron Stock Price Faces Margin Squeeze Despite 17% Revenue Growth - simplywall.st

...

Regeneron Stock Price Faces Margin Squeeze Despite 17% Revenue Growth - simplywall.st
TipRanks 3d
Regeneron and Sanofi Terminate Real‑World Dupilumab Study in Chronic Urticaria

Regeneron Pharmaceuticals (REGN), Sanofi SA (SNY) announced an update on their ongoing clinical study. Unlock powerful investing tools with TipRanks Premium to...

TipRanks 3d
Regeneron price target raised to $737 from $696 at RBC Capital

RBC Capital raised the firm’s price target on Regeneron (REGN) to $737 from $696 and keeps a Sector Perform rating on the shares. The company reported strong sa...

Analyst ratings

68%

of 31 ratings
Buy
67.7%
Hold
32.3%
Sell
0%

More REGN News

Nasdaq 3d
Regeneron Q2 2026 Earnings Call Transcript

AAPL TSLA AMZN META AMD NVDA PEP COST ADBE GOOG AMGN HON INTC INTU NFLX ADP SBUX MRNA AAPL TSLA AMZN META AMD NVDA PEP COST ADBE GOOG AMGN HON INTC INTU NFLX AD...

Regeneron Q2 2026 Earnings Call Transcript
TipRanks 3d
Regeneron Earnings Call Highlights Dupixent-Driven Surge

Regeneron Pharmaceuticals ((REGN)) has held its Q2 earnings call. Read on for the main highlights of the call. Claim 55% Off TipRanks Unlock powerful investing...

Benzinga 4d
Sanofi Says Weak Decision-Making Hurt Pipeline, Promises More Disciplined R&D

Dupixent Drives Growth While Vaccines Sales Decline Dupixent sales increased by 37.6% to 5.154 billion euros, above 5 billion euros per quarter for the first t...

Sanofi Says Weak Decision-Making Hurt Pipeline, Promises More Disciplined R&D
The Wall Street Journal 4d
Health Care Roundup: Market Talk

Yves Herman / Reuters The latest Market Talks covering the Health Care sector. Published exclusively on Dow Jones Newswires at 4:20 ET, 12:20 ET and 16:50 ET....

Health Care Roundup: Market Talk
TipRanks 5d
Regeneron Targets Safer Outpatient Myeloma Care With New Linvoseltamab Study

Regeneron Pharmaceuticals (REGN) announced an update on their ongoing clinical study. Unlock powerful investing tools with TipRanks Premium to make smarter, mo...

TipRanks 6d
Regeneron Pharmaceuticals Lawsuit Alleges Investors Were Misled Before REGN Stock Drops

Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) is facing a federal securities lawsuit alleging that investors were not fully informed about risks tied to a Phas...

Seeking Alpha 6d
Kiniksa tops Q2 estimates on Regeneron-partnered Arcalyst

Kiniksa Pharmaceuticals (KNSA) added nearly 50% on Tuesday after posting another quarterly beat and guidance boost with its financials, thanks mainly to Arcalys...

Kiniksa tops Q2 estimates on Regeneron-partnered Arcalyst

People also own

Based on the portfolios of people who own REGN. This list is generated using Robinhood data, and it’s not a recommendation.

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.

All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer. Options are risky and aren’t suitable for all investors. To learn more about risks, read the Options Disclosure Document.